Hikma Pharmaceuticals Plc 15.6% Potential Upside Indicated by Morgan Stanley

Broker Ratings

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) had its stock rating noted as ‘Upgrades’ with the recommendation being set at ‘OVERWEIGHT’ today by analysts at Morgan Stanley. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Morgan Stanley have set a target price of 2600 GBX on its stock. This is indicating the analyst believes there is a potential upside of 15.6% from the opening price of 2250 GBX. Over the last 30 and 90 trading days the company share price has decreased 32 points and increased 64 points respectively. The 1 year high for the stock price is 2670 GBX while the year low share price is currently 1596 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 2,432.75 GBX and a 200 Day Moving Average share price is recorded at 2,104.28. There are currently 230,449,839 shares in issue with the average daily volume traded being 2,571,729. Market capitalisation for LON:HIK is £5,120,595,422 GBP.

You might also enjoy reading  Hikma Pharmaceuticals Plc 40.4% potential upside indicated by Barclays

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index